Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Reinhard Kage

Allergy & Immunology Manchester, CT Medical Doctor

NPI 1902891013 CMS profile 177546

361 Main St, Manchester, CT 06040

Open in the dashboard

General payments

$10,375

664 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Reinhard Kage of Manchester, CT is reported in the CMS Open Payments database as having received $10,375 across 664 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,322 173
2024 General $2,397 145
2023 General $2,380 144
2022 General $1,222 89
2021 General $933 62
2020 General $579 27
2019 General $542 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reinhard Kage
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Reinhard Kage were reported at $2,322. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Reinhard Kage Allergy & Immunology median Middle half National median
2019 $542 $594 $163–$1,512 $163
2020 $579 $426 $106–$1,233 $114
2021 $933 $638 $157–$1,708 $132
2022 $1,222 $790 $205–$1,961 $149
2023 $2,380 $852 $220–$2,147 $160
2024 $2,397 $865 $203–$2,267 $164
2025 $2,322 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $2,044 243 payments
  2. Amgen Inc. $1,570 108 payments
  3. AbbVie, Inc. $1,151 75 payments
  4. UCB, Inc. $787 43 payments
  5. Novartis Pharmaceuticals Corporation $733 24 payments
  6. Lilly USA, LLC $678 30 payments
  7. Mallinckrodt Hospital Products Inc. $537 35 payments
  8. AstraZeneca Pharmaceuticals LP $443 8 payments
  9. GlaxoSmithKline, LLC. $276 13 payments
  10. Regeneron Healthcare Solutions, Inc. $258 10 payments
  11. Other $1,899 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,085 660 payments
  2. Education $290 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,609 209 payments
  2. TALTZ $649 29 payments
  3. Enbrel $631 46 payments
  4. Otezla $605 56 payments
  5. ACTHAR $537 35 payments
  6. Cimzia $517 24 payments
  7. DUPIXENT $493 10 payments
  8. COSENTYX $472 10 payments
  9. SIMPONI ARIA $435 34 payments
  10. STELARA $435 34 payments
  11. Other $6,236 353 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

664 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record